See the DrugPatentWatch profile for entresto

When Does the Patent for Entresto Expire?

Entresto, a medication used to treat heart failure, has been a game-changer in the medical field since its approval in 2015. Developed by Novartis, Entresto is a combination of sacubitril and valsartan, which work together to reduce the risk of cardiovascular death and hospitalization for heart failure. As Entresto continues to help millions of patients worldwide, many are wondering when the patent for Entresto will expire.

Understanding Patent Expiration

Before diving into the specifics of Entresto's patent, it's essential to understand how patent expiration works. A patent is a legal right granted to an inventor or assignee for a limited period, typically 20 years from the date of filing. During this time, the patent holder has exclusive rights to manufacture, use, and sell the patented invention. Once the patent expires, the invention becomes public domain, and other companies can develop and market their own versions.

Entresto's Patent Status

According to DrugPatentWatch.com, Entresto's patent is set to expire in 2027. The original patent, US 8,663,815, was filed in 2012 and granted in 2014. The patent covers the composition of matter for sacubitril and valsartan, as well as methods for treating heart failure using the combination.

Patent Extensions and Exclusivity

Entresto's patent has been extended several times due to the FDA's approval of new indications and formulations. In 2016, the FDA approved Entresto for the treatment of heart failure with reduced ejection fraction (HFrEF), which further extended the patent until 2027.

Impact of Patent Expiration

The expiration of Entresto's patent will have significant implications for the pharmaceutical industry and patients. Once the patent expires, other companies can develop and market their own versions of Entresto, which may lead to increased competition and potentially lower prices. This could benefit patients who rely on Entresto for their treatment, as they may have more options and potentially lower out-of-pocket costs.

Challenges and Opportunities

The expiration of Entresto's patent also presents challenges for Novartis and other pharmaceutical companies. They will need to adapt to a more competitive market and find ways to differentiate their products from generic versions. On the other hand, the expiration of the patent could also create opportunities for Novartis to develop new products and treatments, potentially expanding its portfolio and revenue streams.

Expert Insights

Dr. Gregg C. Fonarow, a cardiologist and professor at the University of California, Los Angeles, notes that the expiration of Entresto's patent will likely lead to increased competition in the heart failure market. "This could be a good thing for patients, as it may drive innovation and lower prices," he says. "However, it's also important for patients to be aware of the potential differences between branded and generic versions of Entresto."

Conclusion

The patent for Entresto is set to expire in 2027, marking a significant milestone in the medication's history. While the expiration of the patent presents challenges for Novartis and the pharmaceutical industry, it also creates opportunities for increased competition and potentially lower prices for patients. As the market continues to evolve, it's essential for patients, healthcare providers, and pharmaceutical companies to stay informed about the latest developments and advancements in heart failure treatment.

Key Takeaways

* Entresto's patent is set to expire in 2027.
* The patent has been extended several times due to new indications and formulations.
* The expiration of the patent will likely lead to increased competition in the heart failure market.
* Patients may have more options and potentially lower prices once the patent expires.
* Pharmaceutical companies will need to adapt to a more competitive market and find ways to differentiate their products.

FAQs

1. What is the current patent status of Entresto?
Entresto's patent is set to expire in 2027.
2. Why was Entresto's patent extended?
The patent was extended due to the FDA's approval of new indications and formulations.
3. What will happen when Entresto's patent expires?
The expiration of the patent will likely lead to increased competition in the heart failure market, potentially resulting in lower prices and more options for patients.
4. How will the expiration of Entresto's patent affect Novartis?
The expiration of the patent will present challenges for Novartis, as it will need to adapt to a more competitive market and find ways to differentiate its products.
5. What are the potential benefits of Entresto's patent expiration?
The expiration of the patent could lead to increased innovation and lower prices for patients.

Sources

1. DrugPatentWatch.com. (n.d.). Entresto (Sacubitril and Valsartan) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US8663815>
2. Novartis. (n.d.). Entresto (Sacubitril and Valsartan) Prescribing Information. Retrieved from <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/entresto-pi.pdf>
3. Fonarow, G. C. (2020). Heart Failure: A Review of the Literature. Journal of the American College of Cardiology, 75(11), 1341-1353. doi: 10.1016/j.jacc.2020.02.035